Aled Edwards’ vision of science is set to shake the foundation of drug discovery and development as we know it.   The Director of M4K Pharma and CEO of the Structural Genomics Consortium is leading the charge for a more open scientific approach. It’s a parallel universe where scientists can work together and get therapies designed to treat rare diseases in the hands of patients even faster – one that isn’t bound by patents, siloes, and profits.  Join Aled as he discusses the “open science” approach, the current state of the pharmaceutical industry, and what the future holds for genetic biology.Show Notes 

M4K Pharma Open Science for Children's Health 

Structural Genomics Consortium 

The Disruptors - Meet Aled 

A Deadly Brain Cancer in Children 

Tackling DIPG with Open Science 
The Journal of Medicinal Chemistry—Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma 
Resources 

M4K Pharma Open Science for Children's Health 

SGC 
The Disruptors - Meet Aled